FAMILY COURT DRUG TESTING Part 1: The Medical Review Officer

Why It Matters, How It Works, and Why Your Case Depends On It

A positive drug test doesn’t always mean what it looks like. The MRO process determines whether a laboratory-confirmed positive reflects illicit use or a valid prescription — and understanding how that determination is made is critical for every attorney, judge, and GAL handling custody and child welfare matters.

What Is a Medical Review Officer?

A Medical Review Officer — commonly referred to as an MRO — is a licensed physician specifically trained and credentialed to evaluate drug test results. The MRO’s role is not to order or collect the test. It is to receive the confirmed laboratory result, contact the donor, and determine whether a legitimate medical explanation exists for the positive finding.

In practical terms, the MRO is the gatekeeper between a raw laboratory result and the final reported outcome. Without this step, every positive drug test for a prescribed medication — Adderall, Xanax, Suboxone, prescribed opioids — would be reported as a positive, regardless of whether the donor has a valid prescription. That distinction matters enormously in family court.

The MRO does not interpret the test. The MRO determines whether the positive result has a legitimate medical explanation. That single determination changes the entire meaning of the result.

How the MRO Process Works in Family Court

In family court drug testing, the laboratory-confirmed result is distributed first — directly to the attorneys, Guardian ad Litem, and the court. The parties see the result as it comes from the laboratory. This is an important distinction from workplace or DOT testing, where results are routed through the MRO before anyone else sees them.

In the family court context, the sequence is intentional — and it matters.

1. Lab result distribution. When the laboratory confirms a result, it is distributed to all parties on the case. Attorneys, the GAL, and the court receive the confirmed laboratory finding — including any positives — as reported by the lab.

2. MRO review when applicable. If a confirmed positive could be explained by a valid prescription, the testing provider initiates MRO review. This is not a step that the attorney requests — it is a standard part of the process. The MRO contacts the donor, requests disclosure of all prescriptions, and independently verifies each prescription with the prescribing physician or dispensing pharmacy.

3. Verified determination. If the MRO confirms a valid, current prescription that accounts for the positive result, the result is changed to a verified negative. If no valid prescription exists, the result stands as a verified positive. That updated determination is then distributed to the same parties who received the original result.

Why Results Are Distributed Before MRO Review

This sequence exists for a reason that is unique to family court. In custody and child welfare cases, a positive result for a prescribed medication is not always a problem — it can be exactly what the court wants to see.

Consider a parent in a custody case who is prescribed methadone as part of a medication-assisted treatment program for opioid dependence. The court has ordered drug testing. The laboratory confirms a positive result for methadone. The court is now alerted to the this prescription, MRO review confirms it’s valid.  Now the court has actionable information. 

Now consider what happens if the testing provider’s accounts are configured for workplace testing, where every positive is routed through MRO review before distribution. The MRO contacts the donor, confirms the methadone prescription, and issues a verified negative. That verified negative is the only result the attorney, GAL, or judge ever sees. The report simply reads negative — with no indication that the donor tested positive for methadone at all.

The court now has no evidence that the parent is taking their prescribed methadone. There is no documentation of treatment compliance. For all the court knows, the parent could have stopped attending their treatment program entirely — and the test result would look identical. Valuable information has been hidden from the court, not through any intent to deceive, but because the provider’s system was never designed for family court in the first place.

By distributing the laboratory result first — before MRO review — attorneys, GALs, and judges can see that the parent tested positive for methadone. The MRO review then follows to verify the prescription and confirm that the positive reflects prescribed use rather than illicit use. Both pieces of information reach the court. Both matter.

This is not a hypothetical edge case. Many testing providers default to workplace configurations because that is how the majority of their accounts operate. Their systems are built to deliver a clean, final MRO determination — which is exactly what an employer needs, but exactly what a family court does not. When evaluating a testing provider for custody or child welfare cases, attorneys should ask a simple question: will I see the full laboratory result before MRO review, or only after? The answer determines whether the court gets the complete picture or a filtered one.

In family court, a positive drug test for a prescribed medication can be good news. It may confirm that a parent is compliant with a treatment plan ordered by the court. If your testing provider only delivers the MRO-reviewed result, that compliance evidence may never reach you — hidden behind an automatic downgrade to negative.

What the MRO Does Not Do — And Why That Matters

This is where misunderstanding often creeps into family court proceedings, and where attorneys and judges need to be especially careful.

The MRO does not interpret the quantitative value of the result. The MRO’s determination is strictly binary: does a valid prescription exist that explains this positive, yes or no? The MRO does not evaluate whether the concentration in the specimen is consistent with the prescribed dose, whether the donor is taking more than prescribed, or whether the level suggests misuse versus therapeutic use.

This is an important distinction because attorneys and judges sometimes assume that the MRO has evaluated whether the level of the drug in the specimen is “normal” for the stated prescription. They have not. The MRO verified the prescription. That is the full scope of the determination.

A verified negative from the MRO means a valid prescription was confirmed. It does not mean the MRO assessed whether the donor is taking the medication as prescribed, at the correct dose, or in a manner consistent with therapeutic use.

The Quantitative Trap: Why the “Number” Can Mislead

Drug test results — particularly from laboratory-confirmed specimens — include a quantitative value: a precise concentration of the drug or metabolite detected, expressed in nanograms per milliliter (ng/mL). In the hands of an attorney, judge, or GAL without a forensic toxicology background, that number can appear far more informative than it actually is.

The quantitative value cannot determine time, dose or frequency. It cannot tell you how much they took, how often they use, or whether they are impaired. Using the number to predict usage level is not supported by the scientific literature, and doing so is widely considered inappropriate and unreliable.

This is not a gray area. The forensic toxicology community has repeatedly demonstrated that urine drug concentrations are influenced by so many individual variables that drawing conclusions about dose or frequency from a single number is scientifically unsound.

Variables That Affect Urine Drug Concentrations

Variable	Impact on Result
Urine pH	Acidic urine can increase amphetamine concentrations by 3–10x compared to alkaline urine, even at the same dose
Hydration Status	A well-hydrated donor produces dilute urine with lower drug concentrations; a dehydrated donor produces concentrated urine with higher values
Timing of Collection	A specimen collected 2 hours after a dose will look dramatically different from one collected 18 hours later
Individual Metabolism	Genetics, liver enzyme activity, kidney function, age, and body composition all affect how quickly a drug is processed
Body Mass / Fat Content	Lipophilic drugs like THC are stored in fat tissue, which affects both concentration and detection window

Two parents taking the same prescribed dose of the same medication on the same schedule can produce urine concentrations that differ by a factor of ten. That is not a hypothetical — it is a well-documented reality of how urine drug testing works. Any attempt to use the quantitative value to draw conclusions about compliance, misuse, or sobriety is building on a foundation that the science does not support.

Pharmacokinetic Plausibility and Therapeutic Value: Limited from a Single Test, Strengthened by Serial Data

Some physicians and expert witnesses have introduced the concept of pharmacokinetic plausibility — also referred to as therapeutic value — into family court proceedings. The idea is straightforward: if a donor claims to be taking a prescribed dose, shouldn’t the urine concentration fall within a predictable range for that dose? And if it doesn’t, doesn’t that suggest the donor is taking more than prescribed — or obtaining the drug from another source?

On the surface, this reasoning sounds compelling. And the concept is not without scientific foundation — but its reliability depends entirely on how it is applied.

Pharmacokinetics is the study of how the body absorbs, distributes, metabolizes, and eliminates a drug. Pharmacokinetic plausibility — sometimes called therapeutic value — is the argument that a urine drug concentration can be evaluated against expected therapeutic ranges to determine whether it is consistent with a given dose.

The Problem with a Single Specimen

When applied to a single test result, pharmacokinetic plausibility and therapeutic value are unreliable. A peer-reviewed article in Critical Reviews in Clinical Laboratory Sciences noted that urinary concentrations of excreted drugs are subject to numerous variables — including dose, hydration, urine pH, drug half-life, clearance, drug-drug interactions, genetic variations, and the 

time between ingestion and collection — and that these variables make quantitative interpretation of a single test result difficult, if not impossible.

The same person, taking the same dose, on two different days, can produce urine concentrations that differ by a factor of 3 to 10 — simply due to changes in urine pH, hydration, and timing. When a single specimen is compared against a population-level therapeutic reference range, the variability is so significant that no defensible conclusion can be drawn about whether the concentration is consistent with a stated dose.

From a single specimen, therapeutic value conclusions are scientifically unreliable. The variables that influence urine drug concentrations are too numerous and too significant to support forensic-level conclusions from one data point.

How Serial Testing Changes the Equation

However, the published literature also demonstrates that when quantitative results are collected over time, the interpretive value changes significantly.

The same Critical Reviews in Clinical Laboratory Sciences article that cautioned against single-specimen interpretation also noted that quantitative urinary results can assist in differentiating new drug use from previous use, and that spikes in urinary concentration can assist in identifying patterns of drug use. A PMC-published study on objective drug testing confirmed that quantitative results from chromatographic methods can be used to follow serial samples and determine whether metabolite concentrations are rising or falling — which may suggest ongoing use or abstinence. And a study of 500 chronic pain patients published in Pain Physician found that repeated quantitative urine testing improved compliance in nearly 64% of patients who were initially non-compliant, with a separate large-scale retrospective analysis identifying increased adherence with more frequent testing.

What this research tells us is that while a single quantitative result cannot reliably support therapeutic value conclusions, serial quantitative data — collected over weeks or months — builds something a single specimen never can: a donor-specific baseline. When a donor’s results consistently fall within a recognizable corridor over twelve or fifteen collections, a significant departure from that pattern carries far more weight than any comparison to a population average from a textbook.

Pharmacokinetic plausibility and therapeutic value are not junk science — but they require serial data to become defensible. A single result compared to a population average is weak. A significant departure from a donor’s own established baseline, supported by twelve or more prior results, is a fundamentally stronger argument.

The practical takeaway for attorneys: if you or opposing counsel want to introduce therapeutic value arguments in a family court proceeding, the strength of that argument depends on the volume of data behind it. A single test result will not hold up. A serial monitoring history — weekly collections over two to three months — gives therapeutic value conclusions real evidentiary weight. Our next article explores exactly how to build that foundation.

Strengthening the case for Therapeutic Evaluation: In our next article, we explore how serial drug testing changes everything — how a pattern of results can accomplish what a single number never can, and why one test doesn’t tell a story, but many tests can.

When the stakes involve a child’s safety and a family’s future, the testing process should be chosen for what it can actually prove — and the review process should be trusted to professionals who know how to evaluate it. To learn more about family court drug testing and MRO review services, contact TrueTest Labs.mgammel@truetestlabs.com  |  847.258.3966 TrueTest Labs  |  truetestlabs.com  |  Drug Testing Solutions